| Literature DB >> 32556851 |
Roy O Mathew1,2, Robert S Rosenson3, Radmila Lyubarova4, Rafia Chaudhry5, Salvatore P Costa6, Sripal Bangalore7, Mandeep S Sidhu4.
Abstract
Atherosclerotic cardiovascular disease (ASCVD) remains an important contributor of morbidity and mortality in patients with chronic kidney disease (CKD). CKD is recognized as an important risk enhancer that identifies patients as candidates for more intensive low-density lipoprotein (LDL) cholesterol lowering. However, there is controversy regarding the efficacy of lipid-lowering therapy, especially in patients on dialysis. Among patients with CKD, not yet on dialysis, there is clinical trial evidence for the use of statins with or without ezetimibe to reduce ASCVD events. Newer cholesterol lowering agents have been introduced for the management of hyperlipidemia to reduce ASCVD, but these therapies have not been tested in the CKD population except in secondary analyses of patients with primarily CKD stage 3. This review summarizes the role of hyperlipidemia in ASCVD and treatment strategies for hyperlipidemia in the CKD population.Entities:
Keywords: Atherosclerotic cardiovascular disease; Chronic kidney disease; Dyslipidemia; End-stage renal disease; PCSK9 inhibitors
Mesh：
Substances：
Year: 2021 PMID： 32556851 DOI： 10.1007/s10557-020-07020-x
Source DB: PubMed Journal: Cardiovasc Drugs Ther ISSN： 0920-3206 Impact factor: 3.727